Nipocalimab

Therapeutic indications

Nipocalimab is indicated for:

Generalised Myasthenia Gravis (gMG)

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Nipocalimab is indicated as an add-on to standard therapy for the treatment of generalised Myasthenia Gravis (gMG) in adult and adolescent patients aged 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Nipocalimab is contraindicated in the following cases:

Active infection

Infectious disease

Live or live-attenuated vaccines

at least one of
Live organism vaccines
Live viral vaccines

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈